Ocular Therapeutix's eye drug shows benefit over Eylea in late-stage trial
Ocular Therapeutix reported that its experimental drug Axpaxli helped more patients maintain vision than Regeneron's Eylea in a 344-patient late-stage trial, and the company said it will discuss the data with the U.S. FDA and expects to submit a marketing application.
